| 000 | 01295 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250518032031.0 | ||
| 264 | 0 | _c20190808 | |
| 008 | 201908s 0 0 eng d | ||
| 022 | _a1532-1924 | ||
| 024 | 7 |
_a10.1016/j.beha.2019.02.012 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGuru Murthy, Guru Subramanian | |
| 245 | 0 | 0 |
_aMyeloid malignancies after treatment for solid tumours. _h[electronic resource] |
| 260 |
_bBest practice & research. Clinical haematology _c03 2019 |
||
| 300 |
_a40-46 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aChemotherapy, Adjuvant _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGranulocyte Colony-Stimulating Factor _xtherapeutic use |
| 650 | 0 | 4 |
_aHematologic Neoplasms _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMyeloproliferative Disorders _xchemically induced |
| 650 | 0 | 4 |
_aNeoplasms, Second Primary _xmetabolism |
| 650 | 0 | 4 |
_aPlatinum _xadverse effects |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aTopoisomerase II Inhibitors _xadverse effects |
| 700 | 1 | _aAbedin, Sameem | |
| 773 | 0 |
_tBest practice & research. Clinical haematology _gvol. 32 _gno. 1 _gp. 40-46 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.beha.2019.02.012 _zAvailable from publisher's website |
| 999 |
_c29532865 _d29532865 |
||